Biomedical Engineering Reference
In-Depth Information
32. Moghimi, S.M.,
., Methylation of the phosphate oxygen moiety
of phospholipid-methoxy(polyethylene glycol) conjugate prevents
PEGylated liposome-mediated complement activation and anaphyla-
toxin production.
et al
FASEB J
, 2006.
20
(14): pp. 2591-2593.
33. Hamad, I.,
., Complement activation by PEGylated single-walled
carbon nanotubes is independent of C1q and alternative pathway
turnover.
et al
(14): pp. 3797-3803.
34. Li, S.D., and L. Huang, Stealth nanoparticles: high density but sheddable
PEG is a key for tumor targeting.
Mol Immunol
, 2008.
45
J Control Release
, 2010.
145
(3):
pp. 178-181.
35. Wang, X.,
., HFT-T, a targeting nanoparticle, enhances specific
delivery of paclitaxel to folate receptor-positive tumors.
et al
ACS Nano
,
(10): pp. 3165-3174.
36. Torchilin, V.P., Recent advances with liposomes as pharmaceutical
carriers.
2009.
3
Nat Rev Drug Discov
, 2005.
4
(2): pp. 145-160.
37. Berry, G.,
., The use of cardiac biopsy to demonstrate reduced
cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegy-
lated liposomal doxorubicin.
et al
Ann Oncol
, 1998.
9
(7): pp. 711-716.
38. Ewer, M.S.,
et al
., Cardiac safety of liposomal anthracyclines.
Semin
Oncol
, 2004.
31
(6 Suppl. 13): pp. 161-181.
39. Sharma, G.,
., Liposomes as targeted drug delivery systems in the
treatment of breast cancer.
et al
(5): pp. 301-310.
40. Duncan, R., Polymer conjugates as anticancer nanomedicines.
J Drug Target
, 2006.
14
Nat Rev
(9): pp. 688-701.
41. Levchenko, T.S.,
Cancer
, 2006.
6
., Liposome clearance in mice: the effect of a
separate and combined presence of surface charge and polymer
coating.
et al
(1-2): pp. 95-102.
42. Zhang, J.S., F. Liu, and L. Huang, Implications of pharmacokinetic
behavior of lipoplex for its inflammatory toxicity.
Int J Pharm
, 2002.
240
Adv Drug Deliv Rev
,
(5): pp. 689-698.
43. de Fougerolles, A.,
2005.
57
., Interfering with disease: a progress report
on siRNA-based therapeutics.
et al
Nat Rev Drug Discov
, 2007.
6
(6):
pp. 443-453.
44. Spagnou, S., A.D. Miller, and M. Keller, Lipidic carriers of siRNA:
differences in the formulation, cellular uptake, and delivery with
plasmid DNA.
Biochemistry
, 2004.
43
(42): pp. 13348-13356.
45. Peer, D.,
., Systemic leukocyte-directed siRNA delivery revealing
cyclin D1 as an anti-inflammatory target.
et al
Science
, 2008.
319
(5863):
pp. 627-630.
Search WWH ::
Custom Search